This podcast explores the evolving role of precision medicine in acute myeloid leukemia (AML), highlighting advances in molecular profiling, targeted therapies, measurable residual disease (MRD) assessment, and transplantation. Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the Phase I/II KOMET-007 study (NCT05735184) evaluating ziftomenib in combination with intensive chemotherapy for newly diagnosed NPM1-mutated or KMT2A-rearranged AML, while Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, reviews the emerging menin inhibitor landscape.

Robert Negrin, MD, Stanford University, Stanford, CA, discusses the selection of FLT3 inhibitors and the role of FLT3-directed maintenance following allogeneic stem cell transplantation. Jorge Cortes, MD, University of Alabama at Birmingham, Birmingham, AL, presents a quality-adjusted survival analysis of quizartinib in newly diagnosed FLT3-ITD-positive AML. Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, explores the integration of targeted therapies, mutation status, and MRD assessment into transplant decision-making. Finally, Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses revumenib maintenance after transplantation in patients with KMT2A-rearranged or NPM1-mutated AML.